Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Jun 12 · below the Ichimoku cloud · RSI 29 (oversold) · MACD above its signal · 8% above its 52-week low
None of the 29 investors followed here reported a position in NVRS.CN in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a NVRS.CN trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Apr 19, 2026 | Bartch (David Joshua)Director of Issuer | Disposition carried out privately at price 1.10 per share. | 3.05M | $3.35M |
| Mar 17, 2026 | Bartch (David Joshua)Director of Issuer | — | 6.80M | — |
| Mar 17, 2026 | Bartch (David Joshua)Director of Issuer | — | 3.05M | — |
| Mar 9, 2026 | Birmingham (Jason)Director of Issuer | — | 0 | — |
| Mar 5, 2026 | Bartch (David Joshua)Director of Issuer | Exercise of rights at price 0.14 per share. | 6.80M | $965.30K |
| Oct 21, 2025 | Van Empel (Ray)10% Security Holder of Issuer | — | 1 | — |
| Oct 21, 2025 | Van Empel (Ray)10% Security Holder of Issuer | — | 1 | — |
| Oct 20, 2025 | Bartch (David Joshua)Director of Issuer | — | 368.5K | — |
| Oct 20, 2025 | Bartch (David Joshua)Director of Issuer | — | 1.08M | — |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 6.5 | -39.4 | 1000.0 | -14.1 | 9.5 | -39.1 | -15.9 | -87.3 | -48.1 | 0.0 | −77.4% | ||
| 2025 | 0.0 | -50.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 100.0 | -50.0 | -28.0 | 5.6 | 63.2 | −38.0% |
| 2024 | 0.0 | -25.0 | 66.7 | -20.0 | -25.0 | 0.0 | 0.0 | 0.0 | -33.3 | -50.0 | 100.0 | 0.0 | −50.0% |
| 2023 | 33.3 | -13.3 | 21.2 | -49.2 | -1.6 | -30.2 | -27.3 | 37.5 | -36.4 | -14.3 | 0.0 | -83.3 | −95.6% |
| 2022 | 28.6 | -22.2 | -32.1 | -69.5 | -35.2 | -10.6 | -15.5 | -22.5 | 12.7 | -1.6 | 3.3 | -28.6 | −93.6% |
| 2021 | 24.7 | -12.3 | -11.8 | 3.7 | -22.4 | 15.2 | 22.4 | 0.0 | -28.0 | -11.9 | -35.6 | -26.3 | −67.1% |
| 2020 | -25.9 | 10.0 | -31.8 | 66.7 | 508.0 | -1.3 | -35.3 | 3.1 | -49.0 | -23.5 | 59.0 | 37.1 | +214.8% |
| 2019 | 0.0 | -16.7 | -40.0 | -21.5 | -42.5 | 44.3 | 3.4 | -26.4 | -3.0 | -30.8 | -26.7 | -59.1 | −95.0% |
| 2018 | -30.6 | -39.5 | -7.7 | -20.8 | -42.1 | 9.1 | -16.7 | 140.0 | -16.7 | -20.0 | -12.5 | -14.3 | −80.6% |
| 2017 | 8.3 | 19.2 | -12.9 | -18.5 | -18.2 | 5.6 | -5.3 | -5.6 | -17.6 | -28.6 | 100.0 | 210.0 | +158.3% |
| 2016 | -16.7 | -20.0 | 25.0 | 100.0 | -10.0 | -33.3 | -16.7 | 20.0 | 33.3 | 112.5 | 76.5 | -20.0 | +300.0% |
| 2015 | -20.0 | 87.5 | 0.0 | 33.3 | -27.5 | 3.4 | -53.3 | 42.9 | 10.0 | -54.5 | 0.0 | -40.0 | −70.0% |
| 2014 | 100.0 | 180.0 | -28.6 | +300.0% |
No analyst coverage for this instrument.
Noveris Health Sciences Inc., a biotechnology company, engages in developing and commercializing solutions for treating mental health problems and enhancing vitality. The company primarily focuses on treating nicotine addiction and post-traumatic stress disorder. The company has a partnership with Applied Pharmaceutical Innovation for pharmaceutical drug discovery, research, and development on empathogenic and entactogenic compounds. Noveris Health Sciences Inc. was formerly known as Mydecine Innovations Group Inc. and changed its name to Noveris Health Sciences Inc. in February 2026. The company was incorporated in 2013 and is headquartered in Vancouver, Canada.
No recent headlines.